FOSCARNET PACKAGE INSERT PDF

Name of the medicinal product. Foscavir 24 mg/ml Solution for Infusion. 2. Qualitative and quantitative composition. Foscarnet trisodium hexahydrate 24 mg /ml. Package leaflet: Information for the user. Foscavir®. 24 mg/ml Solution for Infusion foscarnet. M UK. Read all of this leaflet carefully before you start. Foscavir™ (Foscarnet Sodium) Injection Product Insert rubber latex has not been used in the manufacture of this device or drug container closure system.

Author: Kagakazahn Gurr
Country: Uzbekistan
Language: English (Spanish)
Genre: Photos
Published (Last): 27 June 2004
Pages: 281
PDF File Size: 7.45 Mb
ePub File Size: 5.51 Mb
ISBN: 648-1-73046-257-6
Downloads: 34355
Price: Free* [*Free Regsitration Required]
Uploader: Malahn

Telavancin has also been associated with QT prolongation.

In vitro foscxrnet have shown that dasatinib has the packgae to prolong the QT interval. Major When possible, avoid concurrent use of foscarnet with other drugs known to prolong the QT interval, such as trazodone. Instruct patients to immediately report symptoms associated with low ionized packxge perioral tingling, extremity numbness, paresthesias that develop during therapy.

Major There packave be an increased risk for QT prolongation and torsade de pointes TdP during concurrent use of mirtazapine and foscarnet. Major Avoid coadministration of gemtuzumab ozogamicin with foscarnet due to the potential for additive QT interval prolongation and risk of torsade de pointes TdP. Systemic pentamidine has also been associated with QT prolongation. Major Avoid coadministration of inotuzumab ozogamicin with foscarnet due to the potential for additive QT interval prolongation and risk of torsade de pointes TdP.

One fatality has been reported from severe hypocalcemia following this combination. Limited data indicate that QT prolongation is also possible with apomorphine administration; however, the change in QTc interval is packaeg significant in most patients receiving dosages within the manufacturer’s guidelines. Perphenazine is also associated with a possible risk for QT prolongation. Tenofovir containing products should be avoided with concurrent or recent use of a nephrotoxic agent; patients receiving concomitant nephrotoxic agents should be carefully monitored for changes in serum creatinine and phosphorus.

  HUSEYIN PAZARCI ULUSLARARASI HUKUK PDF

Acetaminophen; Caffeine; Magnesium Salicylate; Phenyltoloxamine: Foscarney When possible, avoid concurrent use of foscarnet with other drugs known to prolong the QT interval, such as long-acting beta-agonists.

Please note that in these clinical trials, hydration and attention to electrolyte balance was not consistently given; the frequency of some adverse events will be lower when current recommendations are followed see sections 4. Moreover, since Foscavir can reduce serum levels of ionised calcium, extreme caution is advised when used concurrently with other drugs known to influence serum calcium levels, like i.

This site uses cookies.

PDR Search

Foscarnet accumulates in bone and is distributed into cartilage. An additive effect is proposed since seizures have been associated with ciprofloxacin fiscarnet foscarnet independently. Although there are no studies examining the effects of dronedarone in patients receiving other QT prolonging drugs, coadministration of such drugs may result in additive QT prolongation.

Also, abnormal renal function has been observed in clinical practice during the use of foscarnet in combination with saquinavir.

Foscavir 24 mg/ml Solution for Infusion – Summary of Product Characteristics (SmPC) – (eMC)

In Decemberthe FDA foscarnett a black box warning regarding the use of droperidol and its association with QT prolongation and potential for cardiac arrhythmias based on postmarketing surveillance data.

In addition, concurrent use of foscarnet with other medications known to prolong the QT interval should be avoided whenever possible.

Major When possible, avoid concurrent use of foscarnet with other drugs known to prolong the QT interval, such as mefloquine. Foscarnet is only indicated for use in immunocompromised patients with CMV retinitis and mucocutaneous acyclovir-resistant HSV infections.

foscqrnet Darunavir; Cobicistat; Emtricitabine; Tenofovir alafenamide: When use of a diuretic is indicated in patients being treated with foscarnet, consider a thiazide diuretic. QT prolongation and ventricular arrhythmia, including torsade de pointes, have been reported in postmarketing surveillance of foscarnet. Major When possible, avoid concurrent use of foscarnet with other drugs known to prolong the QT fkscarnet, such as ondansetron. Also, the risk of renal toxicity may be increased if foscarnet is used in conjunction with other nephrotoxic agents such as lithium.

  ANTRAX TERRY BROOKS PDF

Mifepristone has been associated with dose-dependent prolongation of the QT interval. Lofexidine prolongs the QT interval. Major Avoid coadministration of foscarnet with foscanet due to the risk of QT prolongation. Rare cases of QT prolongation and TdP have also been reported with ciprofloxacin during postmarketing surveillance.

Severe Thioridazine is associated with a well-established risk of QT prolongation and torsade de pointes TdP. Limited data are available regarding the safety of maprotiline in combination with other QT-prolonging drugs. The physico-chemical stability of foscarnet and dilutions thereof in equal parts with 0. Major When possible, avoid concurrent use of foscarnet with other drugs known to prolong the QT interval, such as escitalopram.

Major When possible, avoid concurrent use of foscarnet with other drugs known to prolong the QT interval, such as apckage trioxide. Minor Concurrent use of foscarnet and zidovudine, ZDV may be associated with a higher incidence of anemia; clinicians should follow normal recommendations for blood count monitoring and other parameters.

Major When possible, avoid concurrent use of foscarnet with other drugs known to prolong the QT interval, such as telavancin. Vandetanib can prolong the QT interval in a concentration-dependent manner. Major When possible, avoid concurrent use of foscarnet with other drugs known to prolong the QT interval, such as anagrelide. Major When possible, avoid concurrent use of foscarnet with other drugs known to prolong the QT interval, such as artemether. Escitalopram has also been associated with a risk of QT prolongation and TdP.

Please refer to section 5. Solifenacin has been associated with dose-dependent prolongation of the QT interval. Electrocardiogram QT prolonged, ventricular arrhythmia, torsade de pointes.